Literature DB >> 7693064

Expression of alpha 2,6-sialylated sugar chains in normal and neoplastic colon tissues. Detection by digoxigenin-conjugated Sambucus nigra agglutinin.

F Dall'Olio1, D Trerè.   

Abstract

It has previously been reported that about 90% of human colon carcinomas express increased levels of the sialyltransferase which adds sialic acid in alpha 2,6 linkage to galactose residues on N-linked chains of glycoproteins. To ascertain whether colon cancer tissues actually express increased amounts of alpha 2,6-sialylated sugar chains on their glycoconjugates, we screened tissue sections of normal colon, benign and malignant colon tumors with digoxigenin-conjugated Sambucus nigra agglutinin (SNA), a NeuAc alpha 2,6Gal/GalNAc-specific lectin. At the concentration of lectin used, epithelial cells of all the 13 normal colon specimens examined were unreactive; 3 out of 8 benign lesions showed a weak reactivity being the remainder unreactive, while 23 out of 26 carcinomas were positive at a variable degree. Qualitative differences were evident among different carcinoma specimens. In some cases a large number of intensely stained intracytoplasmatic particles was present, thus suggesting that reactivity may be associated with secretions, very likely of mucus droplets. In other specimens there was a more uniform distribution of the staining which suggest that reactivity is associated with cell membrane glycoconjugates. These data indicate that the expression of a2,6-sialylated sugar chains is remarkably increased in the majority of colon cancer specimens examined.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693064

Source DB:  PubMed          Journal:  Eur J Histochem        ISSN: 1121-760X            Impact factor:   3.188


  16 in total

Review 1.  Sialyltransferases in cancer.

Authors:  F Dall'Olio; M Chiricolo
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

2.  Protein glycosylation in cancer biology: an overview.

Authors:  F Dall'olio
Journal:  Clin Mol Pathol       Date:  1996-06

3.  Differentiation -dependent expression of human beta-galactoside alpha 2,6-sialyltransferase mRNA in colon carcinoma CaCo-2 cells.

Authors:  F Dall'Olio; N Malagolini; S Guerrini; J T Lau; F Serafini-Cessi
Journal:  Glycoconj J       Date:  1996-02       Impact factor: 2.916

4.  Evaluation of Total and Lipid Bound Sialic Acid in Serum in Oral Leukoplakia.

Authors:  Karthik Krishnan; Sivapathasundharam Balasundaram
Journal:  J Clin Diagn Res       Date:  2017-03-01

5.  Tissue and serum alpha 2-3- and alpha 2-6-linkage specific sialylation changes in oral carcinogenesis.

Authors:  Manisha H Shah; Shaila D Telang; Pankaj M Shah; Prabhudas S Patel
Journal:  Glycoconj J       Date:  2007-12-25       Impact factor: 2.916

6.  The metastatic stage-dependent mucosal expression of sialic acid is a potential marker for targeting colon cancer with cationic polymers.

Authors:  Abdel Kareem Azab; Jackie Kleinstern; Morris Srebnik; Abraham Rubinstein
Journal:  Pharm Res       Date:  2007-10-25       Impact factor: 4.200

7.  Clinicopathologic evaluation of CDw75 antigen expression in colorectal adenocarcinomas.

Authors:  Gülsüm Ozlem Elpek; Tekinalp Gelen; Gülten Karpuzoglu; Tuncer Karpuzoglu; Nazif Hikmet Aksoy; Nuran Keles
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

8.  Clinical usefulness of alterations in sialic acid, sialyl transferase and sialoproteins in breast cancer.

Authors:  G N Raval; L J Parekh; D D Patel; F P Jha; R N Sainger; P S Patel
Journal:  Indian J Clin Biochem       Date:  2004-07

9.  Development of a robust and high throughput method for profiling N-linked glycans derived from plasma glycoproteins by NanoLC-FTICR mass spectrometry.

Authors:  Michael S Bereman; Douglas D Young; Alexander Deiters; David C Muddiman
Journal:  J Proteome Res       Date:  2009-07       Impact factor: 4.466

10.  Sialic acid-binding lectins: submolecular specificity and interaction with sialoglycoproteins and tumour cells.

Authors:  E Fischer; R Brossmer
Journal:  Glycoconj J       Date:  1995-10       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.